Biotech | April 03, 2022
USFDA approves Yescarta as first CAR T-cell therapy for Lymphoma
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
This state-of-art technology will help pulmonologists to diagnose lung cancer in the very early stages helping the patient get an early surgical resection
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Bayer will be setting up 27 telemedicine centres in 12 districts across 8 states with implementing partners Telerad RxDx and Piramal Swasthya
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
Highlights the need for rebuilding, restructuring, and re-imagining resilient healthcare systems in India
An estimated 21 million American women experience BV
Subscribe To Our Newsletter & Stay Updated
